S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
Log in

NASDAQ:MBOT - Microbot Medical Stock Price, Forecast & News

$5.55
-0.19 (-3.31 %)
(As of 03/31/2020 04:00 PM ET)
Today's Range
$5.50
Now: $5.55
$6.02
50-Day Range
$4.42
MA: $7.64
$10.81
52-Week Range
$4.30
Now: $5.55
$20.15
Volume120,832 shs
Average Volume599,031 shs
Market Capitalization$34.88 million
P/E RatioN/A
Dividend YieldN/A
Beta5.16
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. It also holds an intellectual property portfolio that comprises 9 patent families, which include 9 patents granted in the United States, 12 patents granted outside the United States, and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Read More
Microbot Medical logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBOT
CUSIPN/A
Phone781-875-3605

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.40 per share

Profitability

Net Income$-7,240,000.00

Miscellaneous

Employees9
Market Cap$34.88 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive MBOT News and Ratings via Email

Sign-up to receive the latest news and ratings for MBOT and its competitors with MarketBeat's FREE daily newsletter.


Microbot Medical (NASDAQ:MBOT) Frequently Asked Questions

How has Microbot Medical's stock been impacted by COVID-19 (Coronavirus)?

Microbot Medical's stock was trading at $6.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MBOT shares have decreased by 13.0% and is now trading at $5.55. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Microbot Medical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Microbot Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Microbot Medical.

When is Microbot Medical's next earnings date?

Microbot Medical is scheduled to release its next quarterly earnings announcement on Monday, April 6th 2020. View our earnings forecast for Microbot Medical.

How were Microbot Medical's earnings last quarter?

Microbot Medical Inc (NASDAQ:MBOT) announced its quarterly earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.58) EPS for the quarter, beating the Zacks' consensus estimate of ($0.60) by $0.02. View Microbot Medical's earnings history.

When did Microbot Medical's stock split? How did Microbot Medical's stock split work?

Microbot Medical's stock reverse split on Monday, May 9th 2016. The 1-12 reverse split was announced on Friday, May 6th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 6th 2016. An investor that had 100 shares of Microbot Medical stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for MBOT?

1 analysts have issued 1 year price objectives for Microbot Medical's stock. Their forecasts range from $26.00 to $26.00. On average, they anticipate Microbot Medical's stock price to reach $26.00 in the next year. This suggests a possible upside of 368.5% from the stock's current price. View analysts' price targets for Microbot Medical.

What are Wall Street analysts saying about Microbot Medical stock?

Here are some recent quotes from research analysts about Microbot Medical stock:
  • 1. According to Zacks Investment Research, "Microbot Medical Inc. is engaged in the research, design, development and commercialization of micro-robotics assisted medical technologies. Its product candidate includes the Self Cleaning Shunt for the treatment of hydrocephalus and Normal Pressure Hydrocephalus and TipCAT, a self-propelling, semi-disposable endoscope which is being developed initially for use in colonoscopy procedures. Microbot Medical Inc., formerly known as Stemcells, Inc., is headquartered in Hingham, MA. " (3/17/2020)
  • 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $60M, which includes a discounted cash flow (DCF)-based asset value of SCS, assuming 60% probability of approval, 20% discount rate and 2% terminal growth rate." (9/11/2019)

Has Microbot Medical been receiving favorable news coverage?

Press coverage about MBOT stock has been trending positive recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Microbot Medical earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutMicrobot Medical.

Who are some of Microbot Medical's key competitors?

What other stocks do shareholders of Microbot Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Microbot Medical investors own include TransEnterix (TRXC), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Athersys (ATHX), Micron Technology (MU), Sarepta Therapeutics (SRPT), NovaBay Pharmaceuticals (NBY) and Inovio Pharmaceuticals (INO).

Who are Microbot Medical's key executives?

Microbot Medical's management team includes the following people:
  • Mr. Harel Gadot, Co-Founder, Pres, CEO & Chairman (Age 46)
  • Mr. David Ben Naim CPA, M.B.A., Chief Financial Officer (Age 50)
  • Dr. Simon Sharon, CTO & Chairman of Scientific Advisory Board
  • Prof. Moshe Shoham, Co-Founder, Scientific Director & Member of Scientific Advisory Board (Age 67)
  • Dr. Eric C. Leuthardt, Scientific Director & Member of Scientific Advisory Board

What is Microbot Medical's stock symbol?

Microbot Medical trades on the NASDAQ under the ticker symbol "MBOT."

How do I buy shares of Microbot Medical?

Shares of MBOT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Microbot Medical's stock price today?

One share of MBOT stock can currently be purchased for approximately $5.55.

How big of a company is Microbot Medical?

Microbot Medical has a market capitalization of $34.88 million. The biotechnology company earns $-7,240,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Microbot Medical employs 9 workers across the globe. View additional information about Microbot Medical.

What is Microbot Medical's official website?

The official website for Microbot Medical is http://www.microbotmedical.com/.

How can I contact Microbot Medical?

Microbot Medical's mailing address is 25 RECREATION PARK DRIVE UNIT 108, HINGHAM MA, 02043. The biotechnology company can be reached via phone at 781-875-3605 or via email at [email protected]


MarketBeat Community Rating for Microbot Medical (NASDAQ MBOT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  337 (Thanks for Voting!)
Underperform Votes:  262 (Thanks for Voting!)
Total Votes:  599
MarketBeat's community ratings are surveys of what our community members think about Microbot Medical and other stocks. Vote "Outperform" if you believe MBOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: What is systematic risk?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel